Could a common arthritis drug ease skin woes in down syndrome?
NCT ID NCT04246372
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether tofacitinib, a drug already approved for arthritis, is safe and helpful for immune-related skin conditions in people with Down syndrome. 47 adolescents and adults with Down syndrome and skin issues like eczema or psoriasis took the drug. Researchers checked for side effects and measured changes in skin symptoms and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tofacitinib (Xeljanz), an oral drug that blocks interferon signaling
- What this could lead to
- If successful, this could point toward a treatment for skin conditions like eczema or psoriasis in people with Down syndrome.
- What could go wrong
- This is a small, early-phase trial with only 47 participants. The drug may not work for all skin conditions, and serious side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Linda Crnic Institute for Down Syndrome
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill help teens regrow hair lost to alopecia?
- Can new tests unlock hidden cognitive changes in down syndrome?
- Bubble cushions may boost balance in down syndrome
- Can allergy and glaucoma drugs regrow hair when delivered by microneedling?
- Can a common ADHD drug help kids with down syndrome?
- Could childhood trauma fuel skin inflammation?